Premium
Phase I½ Evaluation and Methodology of RO 20–2230 in Postoperative Patients
Author(s) -
BROWN COLIN R.,
SARNQUIST FRANK H.,
CANUP CAROL A.
Publication year - 1979
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1979.tb02468.x
Subject(s) - medicine , administration (probate law) , veterans affairs , law , political science
This report presents the rationale and methodology of our "phase 1 1/2" model for drug evaluation and reports the results of a typical study. We found that Ro 20-2230, and investigational agonist-antagonist analgesic, was well tolerated in therapeutic doses, with 15 mg intramuscular Ro 20-2230 approximately equivalent to 10 mg intramuscular morphine sulfate.